BioLife’s Bothell, Washington manufacturing unit and quality systems are accredited to ISO 13485:2003 and abide by 21 CFR Part 820 – Quality System Regulation once and for all Manufacturing Procedures of medical products, 21 CFR Parts 210 and 211 covering GMP for Aseptic Production, Quantity 4, EU Suggestions, Annex 1 for the Produce of Sterile Medicinal Items, ISO 13408 for aseptic processing of healthcare items, and ISO 14644 for Clean Areas and Associated Controlled Conditions. BioLife and OriGen will be going to, exhibiting, and taking part in panel discussions at the Phacilitate Cell & Gene Therapy meeting, 25-27 January, 2010, in Washington, DC.; OriGen Biomedical, Inc.Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Great Begin GeneticsMelatonin and the circadian rhythm: an interview with Professor Kennaway, University of AdelaideAmputation isn’t wound healingThe big question is whether the benefits of treatment with these medications are offset by adverse effects, in particular thrombosis resulting in an excess threat of heart stroke and attack. This offers been a particular concern with aprotinin and some studies that didn’t use randomisation found an elevated risk of these complications with this drug. However, this Cochrane Overview of randomised managed trials found no upsurge in the risk of thrombosis with aprotinin or tranexamic acid.